The Development of a Vaccine Against Meningococcus B Using Reverse Vaccinology

Neisseria Heparin Binding Antigen is targeted by the human alternative pathway C3-convertase

(2018) Martina Di Fede et al.   PLoS One

Structures of NHBA elucidate a broadly conserved epitope identified by a vaccine induced antibody

(2018) Martina Maritan et al.   PLoS One

NadA3 Structures Reveal Undecad Coiled Coils and LOX1 Binding Regions Competed by Meningococcus B Vaccine-Elicited Human Antibodies

(2018) Alessia Liguori et al.   mBio

Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Portugal

(2017) Maria João Simões et al.   PLoS One

Serogroup B Meningococcus Outbreaks, Prevalence, and the Case for Standard Vaccination

(2017) James Grogan et al.   Current Infectious Disease Reports

Meningococcal Antigen Typing System (MATS)-Based Neisseria meningitidis Serogroup B Coverage Prediction for the MenB-4C Vaccine in the United States

(2017) Gowrisankar Rajam et al.   mSphere

Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study

(2016) Sydel R Parikh et al.   LANCET

Immunogenicity of a Meningococcal B Vaccine during a University Outbreak

(2016) Nicole E. Basta et al.   NEW ENGLAND JOURNAL OF MEDICINE

Predicted Strain Coverage of a New Meningococcal Multicomponent Vaccine (4CMenB) in Spain: Analysis of the Differences with Other European Countries

(2016) Raquel Abad et al.   PLoS One

Expression of factor H binding protein in meningococcal strains can vary at least 15-fold and is genetically determined

(2016) Massimiliano Biagini et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Distribution of Bexsero® Antigen Sequence Types (BASTs) in invasive meningococcal disease isolates: Implications for immunisation

(2016) Carina Brehony et al.   VACCINE

High predicted strain coverage by the multicomponent meningococcal serogroup B vaccine (4CMenB) in Poland

(2016) Izabela Waśko et al.   VACCINE

Neisserial Heparin Binding Antigen (NHBA) Contributes to the Adhesion of Neisseria meningitidis to Human Epithelial Cells

(2016) Irene Vacca et al.   PLoS One

A Large Portion of Meningococcal Antigen Typing System-Negative Meningococcal Strains from Spain Is Killed by Sera from Adolescents and Infants Immunized with 4CMenB

(2015) R. Abad et al.   Clinical and Vaccine Immunology

Neisseria meningitidisfactor H-binding protein fHbp: a key virulence factor and vaccine antigen

(2015) Kate L Seib et al.   Expert Review of Vaccines

MATS: Global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine

(2015) Duccio Medini et al.   VACCINE

Diversity of greek meningococcal serogroup B isolates and estimated coverage of the 4CMenB meningococcal vaccine

(2014) Georgina Tzanakaki et al.   BMC MICROBIOLOGY

Neisseria Adhesin A Variation and Revised Nomenclature Scheme

(2014) Stefania Bambini et al.   Clinical and Vaccine Immunology

Shortcomings of pertussis vaccines: why we need a third generation vaccine

(2014) Jan T Poolman   Expert Review of Vaccines

Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial

(2014) Robert C Read et al.   LANCET

Structure of the meningococcal vaccine antigen NadA and epitope mapping of a bactericidal antibody

(2014) Enrico Malito et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Global Population Structure and Evolution of Bordetella pertussis and Their Relationship with Vaccination

(2014) M. J. Bart et al.   mBio

Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials

(2013) Timo Vesikari et al.   LANCET

Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment

(2013) Ulrich Vogel et al.   LANCET INFECTIOUS DISEASES

Evaluation of Truncated NhhA Protein as a Candidate Meningococcal Vaccine Antigen

(2013) Ian R. Peak et al.   PLoS One

Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage

(2013) Giacomo Frosi et al.   VACCINE

Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB)

(2013) Julie A. Bettinger et al.   VACCINE

Conservation of Meningococcal Antigens in the Genus Neisseria

(2013) A. Muzzi et al.   mBio

Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): Lessons from past programs and implications for the future

(2013) Johan Holst et al.   Human Vaccines & Immunotherapeutics

Transcriptional Regulation of thenadAGene in Neisseria meningitidis Impacts the Prediction of Coverage of a Multicomponent Meningococcal Serogroup B Vaccine

(2012) Luca Fagnocchi et al.   INFECTION AND IMMUNITY

Comparative Long-term Adverse Effects Elicited by Invasive Group B and C Meningococcal Infections

(2011) M. Gottfredsson et al.   CLINICAL INFECTIOUS DISEASES

The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans

(2011) Daniela Toneatto et al.   Human vaccines & immunotherapeutics

Structure of the C-terminal Domain ofNeisseriaHeparin Binding Antigen (NHBA), One of the Main Antigens of a Novel Vaccine againstNeisseria meningitidis

(2011) Veronica Esposito et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Multicenter, Open‐Label, Randomized Phase II Controlled Trial of an Investigational Recombinant Meningococcal Serogroup B Vaccine With and Without Outer Membrane Vesicles, Administered in Infancy

(2010) Jamie Findlow et al.   CLINICAL INFECTIOUS DISEASES

Review of Meningococcal Group B Vaccines

(2010) Dan M. Granoff   CLINICAL INFECTIOUS DISEASES

Immunogenicity of 2 Investigational Serogroup B Meningococcal Vaccines in the First Year of Life

(2010) Matthew D. Snape et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans

(2010) Davide Serruto et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines

(2010) J. Donnelly et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates

(2009) Muriel C. Schneider et al.   NATURE

Structural Basis for the Immunogenic Properties of the Meningococcal Vaccine Candidate LP2086

(2008) Alessandro Mascioni et al.   JOURNAL OF BIOLOGICAL CHEMISTRY